No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Bioton S.A. operates as a biotechnology company, engaged in the creation, production, distribution, and commercialization of a diverse array of pharmaceuticals, medicinal preparations, and active pharmaceutical ingredients. Its primary focus is on diabetes management, offering products such as recombinant human and conventional insulin, alongside oral anti-diabetic medications. The company's portfolio extends to include dietary supplements, blood glucose monitoring strips, and over-the-counter solutions for diabetics. Key insulin products include Gensulin N, Gensulin R, and Gensulin M30, available in vials and cartridges. Complementing these are advanced delivery and monitoring systems like the GensuPen 2 automatic injection device and the GensuCare glucometer for diabetes monitoring, alongside essential needles. Bioton S.A. distributes its offerings across numerous international markets, including Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. Beyond its core product activities, the company also undertakes advertising, advisory services, and general corporate management. Founded in 1989, its headquarters are situated in Ozarów Mazowiecki, Poland.
www.bioton.plNo one on the platform currently holds BIO.WA.
No tracked institution reports a position in BIO.WA as of their last filing.
No one on the platform has traded BIO.WA yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 0.9% | — | — | — | ||
| Rev. Growth % | 36.0% | 5.0% | ||||
| Profit Margin % | 1.2% | -0.5% | -5.2% | |||
| Free Cash Flow Margin % | 0.8% | 3.4% | 1.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $266M | +2.3% | $0.14 | $0.14–$0.14 | — | 1 |
| 2027 | $285M | +7.1% | $0.26 | $0.26–$0.26 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| BIO.WABioton S.a. | $3.70 | -0.27% | $318M | — |
| BCX.WABioceltix S.a. | $75.60 | -0.53% | $418M | — |
| CTX.WACaptor Therapeutics Spolka Akcyjna | $72.50 | +0.28% | $459M | — |
| MAB.WAMabion S.A. | $7.91 | -1.13% | $128M | — |
| MDG.WAMedicalgorithmics S.A. | $25.50 | -1.54% | $254M | — |
| MOC.WAMolecure S.A. | $7.63 | +3.39% | $189M | — |
| MRC.WAMercator Medical S.A. | $57.80 | +0.35% | $529M | — |
Source: Financial Modeling Prep · peers by sector/industry